Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common mineral boost antidepressants? new trial investigates

NCT ID NCT07458022

Symptom relief Sponsor: University of Child Health Sciences and Children's Hospital, Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding magnesium to a standard SSRI antidepressant works better than the SSRI alone for adults with major depressive disorder. Fifty participants will be randomly assigned to receive either the combination or just the SSRI. The main goal is to see if depression scores improve more with the added magnesium after 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
magnesium
What this could lead to
If it works, this could point toward a simple, low-cost way to boost the effectiveness of standard antidepressants for people with major depression.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. It's also not yet clear if adding magnesium is safe or effective long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients of above 18 years diagnosed with DSM who had MDD and receiving SSRI alone and SSRI plus magnesium. Exclusion Criteria: Individuals who recently underwent treatment with electroconvulsive therapy, have a history of epilepsy or other severe neurological problems, have experienced a head injury, are cognitively impaired, and have comorbid conditions such as liver, renal, cardiovascular, neurological, or endocrine, or respiratory problems, or are pregnant or nursing mothers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive diorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive diorder

Contacts and locations

Locations

  • Combined Military Hospital (CMH)

    Multan, Punjab Province, 60000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.